NCT05526313View on ClinicalTrials.gov

Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

September 7, 2022

Study Completion Date

March 29, 2024

Conditions

Diffuse Large B Cell Lymphoma，DLBCL

Interventions

DRUG

Purinostat Mesylate 1.2mg/m^2

1 case,The starting dose,Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 2.4mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 4.0mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 6.0mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 8.4mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 11.2mg/m^2

Take the medicine once on D1, D8, D11, D15.

DRUG

Purinostat Mesylate 15mg/m^2

Take the medicine once on D1, D8, D11, D15.

Trial Locations (1)

610000

West China Hospital Sichuan University, Chengdu

All Listed Sponsors

lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY

NCT05526313 - Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant | Biotech Hunter | Biotech Hunter